Fundamental research for the development of a novel anti-glycan antibody drug against multiple sclerosis

2022 Fiscal Year Final Research Report

• Project/Area Number: 20H03379
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Single-year Grants
• Section: 一般
• Review Section: Basic Section 47030:Pharmaceutical hygiene and biochemistry-related
• Research Institution: Chiba University
• Principal Investigator: KAWASHIMA Hiroto 千葉大学, 大学院薬学研究院, 教授 (50260336)
• Co-Investigator(Kenkyū-buntansha): 小林 基弘 福井大学, 学術研究院医学系部門, 教授 (00362137) ; 安保 博仁 千葉大学, 大学院薬学研究院, 助教 (80868050)
• Project Period (FY): 2020-04-01 – 2023-03-31
• Keywords: リンパ球ホーミング / 高内皮細静脈 / 抗糖鎖抗体 / 多発性硬化症 / 免疫疾患

Outline of Final Research Achievements

Glycans play various physiological roles in development, immunity, canceration, protein quality control, etc. Their functions as the third life chain and their potential as drug discovery targets have recently attracted attention. In this study, we used a newly developed anti-glycan antibody generated by our own methodology to examine its suppressing effects on experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis. We obtained basic data for the development of novel antibody drugs against immune-related diseases.

Free Research Field

免疫学、生化学

Academic Significance and Societal Importance of the Research Achievements

免疫関連疾患の一種である多発性硬化症に関しては、治療薬が開発されているものの、それらには感染症や徐脈性不整脈等の副作用も知られており、作用機序の異なる新規治療薬の開発が望まれる。本研究では、独自に開発した糖鎖に結合する抗体が、多発性硬化症の新しい治療薬の候補となる可能性を検討し、有望な結果を得た。